Drug news
Eviplera triple therapy ( Gilead Sciences) is EU approved for HIV-1 infection
The EMA has granted marketing authorisation for the combination drug Eviplera, from Gilead Sciences, for HIV-1 infection.Eviplera is a once-daily single-tablet that combines Truvada (tenofovir/emtricitabine) from Gilead Sciences and Edurant(rilpivirine) from Tibotec, a Johnson & Johnson company.The combination has been approved by the FDA as Complera.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.